Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643741 · ClinicalTrials.gov registry record
Non-Invasive Preeclampsia Screening and Biobank
A clinical trial of Preeclampsia (PE), sponsored by Sequenom.
- Recruiting
- Registry status
- 6,550
- Enrollment target
- 20
- Study locations
NCT06643741: Recruiting study of Preeclampsia (PE), sponsored by Sequenom.
NCT06643741 is a study of Preeclampsia (PE) that is actively recruiting participants, run by Sequenom. The registered enrollment target is 6,550 participants. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06643741, a study of Preeclampsia (PE), is actively recruiting participants, sponsored by Sequenom.
- RECRUITING
- Registry status
- 6,550 participants
- Enrollment target
- 20
- Study locations
Study Summary
Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
Primary Outcome
The results of the Preeclampsia Screen assay will be compared to pregnancy outcome data to evaluate how well the assay predicted early onset PE (\<34 weeks gestational age) and preterm PE (\<37 weeks gestational age).
Conditions Studied
Study Locations (20)
New Jersey
- Cooper University Health Care - Camden
- New Jersey Perinatal Associates - Livingston
- Rutgers Robert Wood Johnson Medical School - New Brunswick
- Capital Health - Pennington
Texas
- St. David's Women's Center of Texas - Austin
- University of Texas Medical Branch - Galveston
- UT Health - Houston
- HCA Healthcare, Texas Maternal Fetal Medicine - Houston
Pennsylvania
- Geisinger Medical Center - Danville
- University of Pennsylvania Perelman School of Medicine - Philadelphia
- Lewis Katz School of Medicine at Temple University - Philadelphia
New York
- Columbia University Medical Center - New York
- Lenox Hill Hospital - New York
Arizona
- Valley Perinatal - Glendale
Delaware
- Delaware Center for Maternal and Fetal Medicine - Newark
Florida
- D&H National Research Centers - Miami
Louisiana
- Southern Clinical Research Associates - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,550 participants |
| Start Date | 2025-02-02 |
| Est. Completion | 2026-07-01 |
What NCT06643741 shows while recruiting
NCT06643741 is an observational study that tracks outcomes without assigning an intervention. Its 6,550 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Preeclampsia (PE) appearing as the primary indexed condition, and to 0 interventions.
NCT06643741 names 20 study sites across 11 states, led by New Jersey, Texas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06643741 about?
NCT06643741 is a clinical study titled "Non-Invasive Preeclampsia Screening and Biobank". Women pregnant between 11-14 weeks gestation will be enrolled with blood samples collected to evaluate for preeclampsia.
What is the current status of trial NCT06643741?
This trial is currently recruiting. The enrollment target is 6,550 participants. The study started on 2025-02-02. Estimated completion is 2026-07-01.
What conditions does trial NCT06643741 study?
This clinical trial studies the following conditions: Preeclampsia (PE).
Who is sponsoring clinical trial NCT06643741?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06643741 being conducted?
This trial has 20 study locations across Arizona, Delaware, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia (PE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
- NCT05515224 · 6,600 participants · NA
5-Cog 2.0: A Pragmatic Clinical Trial
- NCT00505245 · 6,500 participants
New Assessment System in Measuring Symptom Distress in Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI